Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161239 · ClinicalTrials.gov registry record · NA
LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
A NA study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT00161239: Clinical Trial NA study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00161239 is a NA study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00161239, a NA study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and refractory diseases that are generally treated with chemotherapy. Despite current treatment modalities, only a subset of patients will be cured by the treatment. In this study, four chemotherapeutic agents (L-asparaginase, Methotrexate, Doxil, and Prednisone) will be administered in a combination regimen for patients with relapsed or refractory Peripheral and/or advanced cutaneous T cell lymphoma. Each one of these individual drugs have been shown to have activity to lymphomas. The objective of the study is to determine if the combination of these chemotherapy agents results in higher response and cure rates in this patient population. This will be a single institutional study which will included 32 patients in the Peripheral T cell lymphoma group and 32 patients in the Cutaneous T cell lymphoma group.
Interventions
- DRUG Doxil, Methotrexate, L-Asparaginase, Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-10 |
| Phase | NA |
Why NCT00161239 stopped before completion
NCT00161239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Doxil, Methotrexate, L-Asparaginase, Prednisone is the first listed.
NCT00161239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00161239 about?
NCT00161239 is a clinical study titled "LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma". Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and refractory diseases that are generally treated with chemotherapy. Despite current treatment modalities, only a subset of patients will be cured by the treatment. In this study, four chemotherapeutic agents (L-aspar...
What is the current status of trial NCT00161239?
This trial is currently terminated. It is a NA study. The enrollment target is 64 participants. The study started on 2005-02. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00161239?
The interventions under investigation include: Doxil, Methotrexate, L-Asparaginase, Prednisone (DRUG).
Who is sponsoring clinical trial NCT00161239?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00161239's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia